Comparison of observed and expected numbers of detected cancers in the Research Center for Cancer Prevention and Screening program

Japanese Journal of Clinical Oncology

Volumn 36, Issue 5, 2006, Pages 301-308

  Hamashima, Chisato ^a   Sobue, Tomotaka ^a   Muramatsu, Yukio ^a   Saito, Hiroshi ^a   Moriyama, Noriyuki ^a   Kakizoe, Tadao ^a  

^a NATIONAL CANCER CENTER   (Japan)

Author keywords

Cancer screening; Detection rate; Overdiagnosis; Sensitivity; Sojourn time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BARIUM ENEMA; BREAST CANCER; BREAST EXAMINATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RESEARCH; CANCER SCREENING; CLINICAL OBSERVATION; COLON CANCER; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXPECTATION; FEMALE; FLUOROGRAPHY; GALLBLADDER CANCER; GASTROSCOPY; HEALTH PROGRAM; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; MATHEMATICAL COMPUTING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; OVARY CANCER; PANCREAS CANCER; PAPANICOLAOU TEST; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RECTUM CANCER; RISK BENEFIT ANALYSIS; SAMPLE SIZE; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; STOMACH CANCER; THORAX RADIOGRAPHY; TIME; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COLONOSCOPY; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 33745728453     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl022     Document Type: Article

References (34)

1. Department of Health Statistics and Information Ministry of Health and Welfare. National survey on cancer screening. Tokyo: Society of Public Health Statistics 2000. (in Japanese)
2. Hisamichi S, Tsuji I, Tsubono Y, Nishino Z. The Effectiveness of cancer screening in Japan. In: Hisamichi S, editor. Evidence Report for Cancer Screening in Japan. Sendai: Tohoku University Press 2001;1-16 (in Japanese).
3. Paci E, Duffy SW. Modelling the analysis of breast cancer screening programmes: Sensitivity, lead time and predictive value in Florence District Programme (1975-86). Int J Epidemiol 1991;20:852-8.
4. Ajiki W, Tsukuma H, Oshima A. The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: Estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2004;34:352-6.
5. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992;30:187-210.
6. Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 1995;75:2507-17.
7. Chen HH, Duffy SW, Taber L. A Markov chain method to estimate the tumor progression rate from preclinical phase, sensitivity and positive predictive value for mammography in breast cancer screening. Statistician 1996;86:449-62.
8. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahilin E, Eriksson O, et al. The Gothenburg breast screening trial; first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997;80:2091-99.
9. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations. J Clin Oncol 2001;19:3490-99.
10. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994;344:1594-8.
11. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152:1743-8.
12. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
13. Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU International 2000;85:1078-84.
14. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
15. Auvin A, Maattanen L, Stenman UH, Tammela T, Rannikko S, et al. Lead-time in prostate cancer screening(Finland). Cancer Cause Control 2002;13:279-85.
16. Tornblom M, Eriksson H, Franzen S, Gustafsson O, Lilia H, Norming U, et al. Lead time associated with screening for prostate cancer. Int J Cancer 2004;108:122-9.
17. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003;95:868-78.
18. Watanabe Y, Fukao A. Gastric cancer screening: A summary of the evidence. In: Hisamichi S, editor. Evidence Report for Cancer Screening in Japan. Sendai: Tohoku University Press 2001.
19. Suzuki T. Lung cancer screening: A summary of the evidence. In: Hisamichi S, editor. Evidence Report for Cancer Screening in Japan. Sendai: Tohoku University Press 2001.
20. Sobue T, Hamashima C, Saito H, Matsuda K, Nishida H, Shimada T. Colorectal cancer screening: A summary of the evidence. Jpn J Cancer Chemother 2005;32:901-15 (in Japanese).
21. Launoy G, Smith TC, Duffy SW, Bouvier V. Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. Int J Cancer 1997;73:220-4.
22. Prevost TC, Launoy G, Duffy SW, Chen HH. Estimating sensitivity and sojourn time in screening for colorectal cancer: A comparison of statistical approaches. Am J Epidemiol 1998;148:609-19.
23. Jouve JL, Remontet L, Dancourt V, Benhamiche AM, Faivre J, Esteve J. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening. Br J Cancer 2001;84:1477-81.
24. Weiss W. Implications of tumor growth rate for the natural history of lung cancer. J Occup Med 1984;26:345-52.
25. Walter SD, Kubik A, Parkin DM, Ressigova J Adamec M, Khlat M. The natural history of lung cancer estimated from the results of a randomized trial of screening. Cancer Causes Control 1992;3:115-23.
26. Parkin DM, Moss SM. Lung cancer screening: Improved survival no reduction in deaths - the role of 'overdiagnosis'. Cancer 2000;89:2369-76.
27. Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer. Another look; a different view. Chest 1997;111:754-68.
28. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuiness G, Libby DM, et al. Early Lung Cancer Action Project: Overall design and findings from baseline screening. Lancet 1999;354:99-105.
29. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: Anti-Lung Cancer Association Project. J Clin Oncol 20:911-20.
30. Schroder FH, Roobol-Bouts M, Vis AN, Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination. Urology 2001;57:83-90.
31. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002; 60:469-73.
32. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Eng J Med 2004;350:2239-46.
33. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293: 2095-101.
34. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Eng J Med 2005;352:1977-84.